ReviewThe Psychiatric quarterly2026
Ecological Momentary Assessment of Emotion Dysregulation in Attention-Deficit/ Hyperactivity Disorder: A Systematic Review.
Review in The Psychiatric quarterly, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Emotion dysregulation (ED) is a hallmark of attention-deficit/ hyperactivity disorder (ADHD); however, routine retrospective evaluations neglect its dynamic nature. To address this limitation, Ecological Momentary Assessment (EMA) provides a useful methodology for collecting data in real time and in participants' natural surroundings. The current systematic review synthesizes findings from EMA studies on emotion dysregulation in ADHD. Systematic searches were conducted through April 2025 across three databases (PubMed, Scopus, and Web of Science). We included 33 studies, with approximately 2678 participants. Findings demonstrate that EMA successfully captures variation in emotion dysregulation while relating it to negative affect and functional impairment, regardless of age. Compliance rates (60-99%) confirm feasibility; however, studies with larger sample sizes and longitudinal data, particularly conducted with adolescents, are required. By providing "real-time" insight into the everyday dynamics of ADHD, the evidence compiled in this review offers a strong basis for the clinical use of EMA in patient management.
Indexed as
Identifiers
42126465What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.